Heusinkveld LE,Majumdar S,Gao JL,McDermott DH,Murphy PM .2019 .WHIM Syndrome: from pathogenesis towards personalized medicine and cure. Journal of Clinical Immunology, 39(6) : 532-556.
Immunological reviews .2019 .. , 287(1) : 91-102.
Majumdar S,Murphy PM .2018 .Adaptive immunodeficiency in WHIM syndrome. International Journal of Molecular Sciences, 20(1) : 3.
Janssens R,Struyf S,Proost P .2018 .Pathological roles of the homeostatic chemokine CXCL12. Cytokine Growth Factor Reviews, 44 : 51-68.
Rodríguez-Frade JM,González-Granado LI,Santiago CA,Mellado M. .2024 .The complex nature of CXCR4 mutations in WHIM syndrome. , 15 : 1406532.
.2024 .Expanding CXCR4 variant landscape in WHIM syndrome: integrating clinical and functional data for variant interpretation. , 15 : 1411141.
Part C .2022 .. , 190(2) : 215-221.
SM. Mavorixafor Hoy .2024 .. , 84(8) : 969-975.
Blood .2024 .. , 144(1) : 1-2.
Book Orange .2024 .Approved Drug Products with Therapeutic Equivalence Evaluations. cfm (Accessed on June 30, : .
.2024 .Center For Drug Evaluation and Research. Product Quality Review(s). pdf (Accessed on June 30, : .
.2024 .. pdf (Accessed on June 30, : .
.2024 .. Accessed on July 25, : .
.2024 .Center For Drug Evaluation and Research. Risk Assessment and Risk Mitigation Review(s). pdf (Accessed on June 30, : .
.2024 .Center For Drug Evaluation and Research. Integrated review. pdf (Accessed on June 30, : .
.2024 .Center For Drug Evaluation and Research. pdf (Accessed on June 30, : .
Andtbacka RHI,Wang Y,Pierce RH,Campbell JS,Yushak M .2022 .Mavorixafor, an Orally Bioavailable CXCR4 Antagonist, Increases Immune Cell Infiltration and Inflammatory Status of Tumor Microenvironment in Patients with Melanoma. Cancer Research Communications, 2(8) : 904-913.
Choueiri TK,Atkins MB,Rose TL,Alter RS,Ju Y . .A phase 1b trial of the CXCR4 inhibitor mavorixafor and nivolumab in advanced renal cell carcinoma patients with no prior response to nivolumab monotherapy.. , : .
New Investigational,Drugs Investigational .2021 .. , 39(4) : 1019-1027.
.2020 .Results of a phase 2 trial of an oral CXCR4 antagonist, mavorixafor, for treatment of WHIM syndrome. Blood, 136(26) : 2994-3003.
.2024 .A phase 3 randomized trial of mavorixafor, a CXCR4 antagonist, for WHIM syndrome. Blood, 144(1) : 35-45.
.2020 .Results of a phase 2 trial of an oral CXCR4 antagonist, mavorixafor, for treatment of WHIM syndrome. Blood, 136(26) : 2994-3003.
.2012 .The molecular pharmacology of AMD11070: an orally bioavailable CXCR4 HIV entry inhibitor. Biochemical pharmacology, 83(4) : 472-479.
Hudu SA,Elmigdadi F,Qtaitat AA,Almehmadi M,Alsaiari AA .2023 .Trofinetide for Rett Syndrome: Highlights on the Development and Related Inventions of the First USFDAApproved Treatment for Rare Pediatric Unmet Medical Need. Journal of Clinical Medicine, 12(15) : 5114.
Hudu SA,Alshrari AS,Al Qtaitat A,Imran M. . .VP37 protein inhibitors for Mpox treatment: Highlights on recent advances, patent literature, and future directions. , : .
Biomedicines .2023 .. , 11(4) : 1106.
Biomedicines .2023 .. , 11(2) : 426.
KMJ Brands .2020 .Compositions of CXCR4 inhibitors and methods of preparation and use. United States Patent Number US10548889B1, : .
Arbeit RD,Ragan PM .2020 .Methods for treating immunodeficiency disease. United States Patent Number US10610527B2, : .
Ragan PM,Arbeit RD,Crowley KJ .2021 .Methods for treating cancer. United States Patent Number US10953003B2, : .
KM Brands .2021 .Compositions of CXCR4 inhibitors and methods of preparation and use. United States Patent Number US11045461B2, : .
Arbeit RD,Ragan PM .2022 .Methods for treating immunodeficiency disease. United States Patent Number US11219621B2, : .
.2022 .Methods for treating cancer. United States Patent Number US11357742B2, : .
Johnson VA,Cramer YS,Rosenkranz SL,Becker S,Klingman KL . .Antiretroviral Activity of AMD11070 (An Orally Administered CXCR4 Entry Inhibitor): Results of NIH/NIAID AIDS Clinical Trials Group Protocol A5210. , : .
.2019 .. AIDS Research and Human Retroviruses, 35(8) : 691-697.
Tripathi R .2023 .Preliminary study to identify CXCR4 inhibitors as potential therapeutic agents for Alzheimer's and Parkinson's diseases. Integrative Biology (Camb), 15 : zyad012.
Miao M,De Clercq E,Li G. .2020 .Clinical significance of chemokine receptor antagonists. Expert Opinion on Drug Metabolism & Toxicology, 16(1) : 11-30.
Uchida D,Kuribayashi N,Kinouchi M,Sawatani Y,Shimura M .2018 .Effect of a novel orally bioavailable CXCR4 inhibitor, AMD070, on the metastasis of oral cancer cells. Oncology Reports, 40(1) : 303-308.
Hanselmann R,Brands KMJ .2023 .Synthesis of mavorixafor and intermediates thereof. WO2023059903A1, : .
Hines D,Hines R .2023 .Methods of treating 5HT2a receptormediated conditions. WO2023212244A1, : .
Arkin I,Singh TPP,Krugliak M. .2023 .E protein channel blockers and orf3 inhibitors as anti-covid-19 agents. US2023190769A1, : .
Zhang Y,Liu D,He H,Ma M,Wang J .2024 .Double-targeting tumor microenvironment response multifunctional nano delivery system and preparation method and application thereof. Chinese Patent Number CN115252790B, : .
Imran M,Khan SA,Alshrari AS,Eltahir Mudawi MM .2022 .Small molecules as kinetoplastid specific proteasome inhibitors for leishmaniasis: a patent review from 1998 to 2021. , 32(5) : 591-604.
Imran M,Khan SA,Alshammari MK,Alqahtani AM,Alanazi TA .2022 .Discovery, Development, Inventions and Patent Review of Fexinidazole: The First All-Oral Therapy for Human African Trypanosomiasis. Pharmaceuticals (Basel), 15(2) : 128.
Imran M,Alshrari AS,Thabet HK .2021 .Synthetic molecules as DprE1 inhibitors: A patent review. Expert Opinion on Therapeutic Patents, 31(8) : 759-772.
Nyunt MM,Becker S,MacFarland RT,Chee P,Scarborough R .2008 .Pharmacokinetic effect of AMD070, an Oral CXCR4 antagonist, on CYP3A4 and CYP2D6 substrates midazolam and dextromethorphan in healthy volunteers. Journal of Acquired Immune Deficiency Syndromes, 47(5) : 559-565.
Cao YJ,Flexner CW,Dunaway S,Park JG,Klingman K .2008 .Effect of low-dose ritonavir on the pharmacokinetics of the CXCR4 antagonist AMD070 in healthy volunteers. Antimicrobial Agents and Chemotherapy, 52(5) : 1630-1634.
. .To read the copy of this license please visit: https://creativecommons. , : .